Published in Annu Rev Med on January 01, 2011
CNVs: harbingers of a rare variant revolution in psychiatric genetics. Cell (2012) 4.81
Mutations causing syndromic autism define an axis of synaptic pathophysiology. Nature (2011) 4.13
FMRP targets distinct mRNA sequence elements to regulate protein expression. Nature (2012) 2.95
Negative allosteric modulation of the mGluR5 receptor reduces repetitive behaviors and rescues social deficits in mouse models of autism. Sci Transl Med (2012) 2.70
Synaptic dysfunction in neurodevelopmental disorders associated with autism and intellectual disabilities. Cold Spring Harb Perspect Biol (2012) 2.42
The pathophysiology of fragile X (and what it teaches us about synapses). Annu Rev Neurosci (2012) 2.16
Modeling autism by SHANK gene mutations in mice. Neuron (2013) 1.64
Ablation of Fmrp in adult neural stem cells disrupts hippocampus-dependent learning. Nat Med (2011) 1.47
Translating glutamate: from pathophysiology to treatment. Sci Transl Med (2011) 1.42
The unstable repeats--three evolving faces of neurological disease. Neuron (2013) 1.26
Uncoupling of the endocannabinoid signalling complex in a mouse model of fragile X syndrome. Nat Commun (2012) 1.24
New perspectives on the biology of fragile X syndrome. Curr Opin Genet Dev (2012) 1.23
Unique signaling profiles of positive allosteric modulators of metabotropic glutamate receptor subtype 5 determine differences in in vivo activity. Biol Psychiatry (2012) 1.22
Development of allosteric modulators of GPCRs for treatment of CNS disorders. Neurobiol Dis (2013) 1.20
High-throughput sequencing of mGluR signaling pathway genes reveals enrichment of rare variants in autism. PLoS One (2012) 1.14
Fragile X mental retardation protein and synaptic plasticity. Mol Brain (2013) 1.12
Inhibition of GSK3β improves hippocampus-dependent learning and rescues neurogenesis in a mouse model of fragile X syndrome. Hum Mol Genet (2011) 1.09
The BCM theory of synapse modification at 30: interaction of theory with experiment. Nat Rev Neurosci (2012) 1.08
Genetic manipulation of STEP reverses behavioral abnormalities in a fragile X syndrome mouse model. Genes Brain Behav (2012) 1.08
Successful cognitive aging in rats: a role for mGluR5 glutamate receptors, homer 1 proteins and downstream signaling pathways. PLoS One (2012) 1.07
Translational animal models of autism and neurodevelopmental disorders. Dialogues Clin Neurosci (2012) 1.06
Genes, circuits, and precision therapies for autism and related neurodevelopmental disorders. Science (2015) 1.05
Autism spectrum disorder causes, mechanisms, and treatments: focus on neuronal synapses. Front Mol Neurosci (2013) 1.04
Cellular and synaptic network defects in autism. Curr Opin Neurobiol (2012) 1.02
STX209 (arbaclofen) for autism spectrum disorders: an 8-week open-label study. J Autism Dev Disord (2014) 1.02
Experience-induced Arc/Arg3.1 primes CA1 pyramidal neurons for metabotropic glutamate receptor-dependent long-term synaptic depression. Neuron (2013) 1.00
Autism spectrum disorders: from genes to neurobiology. Curr Opin Neurobiol (2014) 0.99
Drug discovery for autism spectrum disorder: challenges and opportunities. Nat Rev Drug Discov (2013) 0.99
An evo-devo approach to thyroid hormones in cerebral and cerebellar cortical development: etiological implications for autism. Front Endocrinol (Lausanne) (2014) 0.98
Defining genetically meaningful language and personality traits in relatives of individuals with fragile X syndrome and relatives of individuals with autism. Am J Med Genet B Neuropsychiatr Genet (2012) 0.96
Excess protein synthesis in FXS patient lymphoblastoid cells can be rescued with a p110β-selective inhibitor. Mol Med (2012) 0.96
Redefining the classification of AMPA-selective ionotropic glutamate receptors. J Physiol (2011) 0.95
Neuronal connectivity as a convergent target of gene × environment interactions that confer risk for Autism Spectrum Disorders. Neurotoxicol Teratol (2012) 0.95
Subcellular fractionation and localization studies reveal a direct interaction of the fragile X mental retardation protein (FMRP) with nucleolin. PLoS One (2014) 0.94
Dysregulation of group-I metabotropic glutamate (mGlu) receptor mediated signalling in disorders associated with Intellectual Disability and Autism. Neurosci Biobehav Rev (2014) 0.94
GABAergic circuit dysfunctions in neurodevelopmental disorders. Front Psychiatry (2012) 0.94
Metabotropic glutamate receptor I (mGluR1) antagonism impairs cocaine-induced conditioned place preference via inhibition of protein synthesis. Neuropsychopharmacology (2013) 0.93
Treatment of neurodevelopmental disorders in adulthood. J Neurosci (2012) 0.93
RAN translation at CGG repeats induces ubiquitin proteasome system impairment in models of fragile X-associated tremor ataxia syndrome. Hum Mol Genet (2015) 0.92
The utility of patient specific induced pluripotent stem cells for the modelling of Autistic Spectrum Disorders. Psychopharmacology (Berl) (2013) 0.91
Astrocytes conspire with neurons during progression of neurological disease. Curr Opin Neurobiol (2012) 0.90
Therapeutic approaches for shankopathies. Dev Neurobiol (2013) 0.90
Phelan McDermid Syndrome: From Genetic Discoveries to Animal Models and Treatment. J Child Neurol (2015) 0.90
Human intellectual disability genes form conserved functional modules in Drosophila. PLoS Genet (2013) 0.89
Genetic disruption of voltage-gated calcium channels in psychiatric and neurological disorders. Prog Neurobiol (2015) 0.89
Norepinephrine drives persistent activity in prefrontal cortex via synergistic α1 and α2 adrenoceptors. PLoS One (2013) 0.88
Arf6-GEF BRAG1 regulates JNK-mediated synaptic removal of GluA1-containing AMPA receptors: a new mechanism for nonsyndromic X-linked mental disorder. J Neurosci (2012) 0.88
Intracellular mGluR5 can mediate synaptic plasticity in the hippocampus. J Neurosci (2014) 0.86
Comprehensive neurocognitive endophenotyping strategies for mouse models of genetic disorders. Prog Neurobiol (2012) 0.86
Common variants in genes of the postsynaptic FMRP signalling pathway are risk factors for autism spectrum disorders. Hum Genet (2014) 0.85
Long-term memory deficits are associated with elevated synaptic ERK1/2 activation and reversed by mGluR5 antagonism in an animal model of autism. Neuropsychopharmacology (2014) 0.85
Pharmacotherapy for the core symptoms in autistic disorder: current status of the research. Drugs (2013) 0.85
Location-dependent signaling of the group 1 metabotropic glutamate receptor mGlu5. Mol Pharmacol (2014) 0.85
Group 1 metabotropic glutamate receptor function and its regulation of learning and memory in the aging brain. Front Pharmacol (2012) 0.85
Shank mutant mice as an animal model of autism. Philos Trans R Soc Lond B Biol Sci (2013) 0.85
Learning and behavioral deficits associated with the absence of the fragile X mental retardation protein: what a fly and mouse model can teach us. Learn Mem (2014) 0.85
Alteration by p11 of mGluR5 localization regulates depression-like behaviors. Mol Psychiatry (2015) 0.84
Recent challenges to the psychiatric diagnostic nosology: a focus on the genetics and genomics of neurodevelopmental disorders. Int J Epidemiol (2014) 0.84
EphA7 signaling guides cortical dendritic development and spine maturation. Proc Natl Acad Sci U S A (2014) 0.84
Lighting a path: genetic studies pinpoint neurodevelopmental mechanisms in autism and related disorders. Dialogues Clin Neurosci (2012) 0.84
Roles of CREB in the regulation of FMRP by group I metabotropic glutamate receptors in cingulate cortex. Mol Brain (2012) 0.83
Autism spectrum disorders: emerging mechanisms and mechanism-based treatment. Front Cell Neurosci (2015) 0.82
PKC phosphorylation regulates mGluR5 trafficking by enhancing binding of Siah-1A. J Neurosci (2012) 0.82
Influence of stimulant-induced hyperactivity on social approach in the BTBR mouse model of autism. Neuropharmacology (2012) 0.82
mGluR5 knockout mice display increased dendritic spine densities. Neurosci Lett (2012) 0.82
mGluR5 ablation in cortical glutamatergic neurons increases novelty-induced locomotion. PLoS One (2013) 0.82
Fragile X syndrome: mechanistic insights and therapeutic avenues regarding the role of potassium channels. Curr Opin Neurobiol (2012) 0.82
Increasing our understanding of human cognition through the study of Fragile X Syndrome. Dev Neurobiol (2013) 0.82
Fragile X-like behaviors and abnormal cortical dendritic spines in cytoplasmic FMR1-interacting protein 2-mutant mice. Hum Mol Genet (2014) 0.81
PDE-4 inhibition rescues aberrant synaptic plasticity in Drosophila and mouse models of fragile X syndrome. J Neurosci (2015) 0.81
Cut-like homeobox 1 and nuclear factor I/B mediate ENGRAILED2 autism spectrum disorder-associated haplotype function. Hum Mol Genet (2011) 0.81
Evaluation of current pharmacological treatment options in the management of Rett syndrome: from the present to future therapeutic alternatives. Curr Clin Pharmacol (2013) 0.80
Neuroligins provide molecular links between syndromic and nonsyndromic autism. Sci Signal (2013) 0.80
Gestational and early postnatal hypothyroidism alters VGluT1 and VGAT bouton distribution in the neocortex and hippocampus, and behavior in rats. Front Neuroanat (2015) 0.80
Fragile X mental retardation protein controls ion channel expression and activity. J Physiol (2016) 0.80
2-Methyl-6-(phenylethynyl) pyridine (MPEP) reverses maze learning and PSD-95 deficits in Fmr1 knock-out mice. Front Cell Neurosci (2014) 0.79
Development of [(123)I]IPEB and [(123)I]IMPEB as SPECT Radioligands for Metabotropic Glutamate Receptor Subtype 5. ACS Med Chem Lett (2014) 0.78
Pathological plasticity in fragile X syndrome. Neural Plast (2012) 0.78
Drep-2 is a novel synaptic protein important for learning and memory. Elife (2014) 0.78
Drug development in pediatric psychiatry: current status, future trends. Child Adolesc Psychiatry Ment Health (2012) 0.77
Advancing the discovery of medications for autism spectrum disorder using new technologies to reveal social brain circuitry in rodents. Psychopharmacology (Berl) (2014) 0.77
Gene expression analysis in Fmr1KO mice identifies an immunological signature in brain tissue and mGluR5-related signaling in primary neuronal cultures. Mol Autism (2015) 0.77
Impaired survival of neural progenitor cells in dentate gyrus of adult mice lacking fMRP. Hippocampus (2011) 0.77
Extinction of an instrumental response: a cognitive behavioral assay in Fmr1 knockout mice. Genes Brain Behav (2014) 0.77
Sequence of Molecular Events during the Maturation of the Developing Mouse Prefrontal Cortex. Mol Neuropsychiatry (2015) 0.76
Prioritizing the development of mouse models for childhood brain disorders. Neuropharmacology (2015) 0.76
Event-related potential alterations in fragile X syndrome. Front Hum Neurosci (2012) 0.76
Sensory-Derived Glutamate Regulates Presynaptic Inhibitory Terminals in Mouse Spinal Cord. Neuron (2016) 0.76
Rsk2 Knockdown in PC12 Cells Results in Sp1 Dependent Increased Expression of the Gria2 Gene, Encoding the AMPA Receptor Subunit GluR2. Int J Mol Sci (2013) 0.76
Matrix metalloproteinases in autism spectrum disorders. J Mol Psychiatry (2013) 0.76
High-throughput screen detects calcium signaling dysfunction in typical sporadic autism spectrum disorder. Sci Rep (2017) 0.76
Structural-functional connectivity deficits of neocortical circuits in the Fmr1 (-/y) mouse model of autism. Sci Adv (2015) 0.76
Effects of bumetanide on neurobehavioral function in children and adolescents with autism spectrum disorders. Transl Psychiatry (2017) 0.75
Progress toward therapeutic potential for AFQ056 in Fragile X syndrome. J Exp Pharmacol (2013) 0.75
c-Jun N-terminal kinase regulates mGluR-dependent expression of post-synaptic FMRP target proteins. J Neurochem (2013) 0.75
Unfolding neurodevelopmental disorders: found in translation. Nat Med (2011) 0.75
Trialing targeted therapies for autism. Nat Med (2012) 0.75
The PI3K signaling pathway as a pharmacological target in Autism related disorders and Schizophrenia. Mol Cell Ther (2016) 0.75
Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome. Cell (1991) 17.00
Functional impact of global rare copy number variation in autism spectrum disorders. Nature (2010) 14.66
Advances in autism genetics: on the threshold of a new neurobiology. Nat Rev Genet (2008) 12.18
Neuroligins and neurexins link synaptic function to cognitive disease. Nature (2008) 9.23
The mGluR theory of fragile X mental retardation. Trends Neurosci (2004) 8.88
Theory for the development of neuron selectivity: orientation specificity and binocular interaction in visual cortex. J Neurosci (1982) 8.62
SINGLE-CELL RESPONSES IN STRIATE CORTEX OF KITTENS DEPRIVED OF VISION IN ONE EYE. J Neurophysiol (1963) 8.01
Reversal of neurological defects in a mouse model of Rett syndrome. Science (2007) 7.09
Correction of fragile X syndrome in mice. Neuron (2007) 6.51
Altered synaptic plasticity in a mouse model of fragile X mental retardation. Proc Natl Acad Sci U S A (2002) 6.45
Homosynaptic long-term depression in area CA1 of hippocampus and effects of N-methyl-D-aspartate receptor blockade. Proc Natl Acad Sci U S A (1992) 6.37
Fragile X syndrome: loss of local mRNA regulation alters synaptic development and function. Neuron (2008) 6.26
Role for rapid dendritic protein synthesis in hippocampal mGluR-dependent long-term depression. Science (2000) 5.28
Reversal of learning deficits in a Tsc2+/- mouse model of tuberous sclerosis. Nat Med (2008) 5.15
FMR1 protein: conserved RNP family domains and selective RNA binding. Science (1993) 4.77
Abnormal dendritic spines in fragile X knockout mice: maturation and pruning deficits. Proc Natl Acad Sci U S A (1997) 4.73
A marker X chromosome. Am J Hum Genet (1969) 4.68
Fragile sites on human chromosomes: demonstration of their dependence on the type of tissue culture medium. Science (1977) 4.59
Fmr1 knockout mice: a model to study fragile X mental retardation. The Dutch-Belgian Fragile X Consortium. Cell (1994) 4.43
Pharmacological rescue of synaptic plasticity, courtship behavior, and mushroom body defects in a Drosophila model of fragile X syndrome. Neuron (2005) 4.11
Suppression of two major Fragile X Syndrome mouse model phenotypes by the mGluR5 antagonist MPEP. Neuropharmacology (2005) 4.09
Fragile X mental retardation protein is translated near synapses in response to neurotransmitter activation. Proc Natl Acad Sci U S A (1997) 4.03
Evidence that fragile X mental retardation protein is a negative regulator of translation. Hum Mol Genet (2001) 3.91
The autistic neuron: troubled translation? Cell (2008) 3.81
Dysregulation of mTOR signaling in fragile X syndrome. J Neurosci (2010) 3.73
A decade of molecular studies of fragile X syndrome. Annu Rev Neurosci (2002) 3.54
Dendritic spine structural anomalies in fragile-X mental retardation syndrome. Cereb Cortex (2000) 3.43
Dynamic translational and proteasomal regulation of fragile X mental retardation protein controls mGluR-dependent long-term depression. Neuron (2006) 3.37
Internalization of ionotropic glutamate receptors in response to mGluR activation. Nat Neurosci (2001) 3.34
Dendritic mRNA: transport, translation and function. Nat Rev Neurosci (2007) 3.29
2-Methyl-6-(phenylethynyl)-pyridine (MPEP), a potent, selective and systemically active mGlu5 receptor antagonist. Neuropharmacology (1999) 3.25
Prevalence of parent-reported diagnosis of autism spectrum disorder among children in the US, 2007. Pediatrics (2009) 3.24
Partial reversal of Rett Syndrome-like symptoms in MeCP2 mutant mice. Proc Natl Acad Sci U S A (2009) 3.23
The fragile X mental retardation protein inhibits translation via interacting with mRNA. Nucleic Acids Res (2001) 3.18
Advances in the treatment of fragile X syndrome. Pediatrics (2009) 3.10
Two distinct forms of long-term depression coexist in CA1 hippocampal pyramidal cells. Neuron (1997) 3.01
Pharmacological inhibition of mTORC1 suppresses anatomical, cellular, and behavioral abnormalities in neural-specific Pten knock-out mice. J Neurosci (2009) 2.90
The pathophysiology of fragile x syndrome. Annu Rev Genomics Hum Genet (2007) 2.85
Deletion of FMR1 in Purkinje cells enhances parallel fiber LTD, enlarges spines, and attenuates cerebellar eyelid conditioning in Fragile X syndrome. Neuron (2005) 2.82
A pilot open label, single dose trial of fenobam in adults with fragile X syndrome. J Med Genet (2009) 2.76
Chemical induction of mGluR5- and protein synthesis--dependent long-term depression in hippocampal area CA1. J Neurophysiol (2001) 2.76
Analysis of neocortex in three males with the fragile X syndrome. Am J Med Genet (1991) 2.70
The HMG-CoA reductase inhibitor lovastatin reverses the learning and attention deficits in a mouse model of neurofibromatosis type 1. Curr Biol (2005) 2.62
Metabotropic receptor-dependent long-term depression persists in the absence of protein synthesis in the mouse model of fragile X syndrome. J Neurophysiol (2006) 2.57
Neuroligin-1 deletion results in impaired spatial memory and increased repetitive behavior. J Neurosci (2010) 2.57
A new function for the fragile X mental retardation protein in regulation of PSD-95 mRNA stability. Nat Neurosci (2007) 2.54
Rescue of behavioral phenotype and neuronal protrusion morphology in Fmr1 KO mice. Neurobiol Dis (2008) 2.52
Hypersensitivity to mGluR5 and ERK1/2 leads to excessive protein synthesis in the hippocampus of a mouse model of fragile X syndrome. J Neurosci (2010) 2.42
Postadolescent changes in regional cerebral protein synthesis: an in vivo study in the FMR1 null mouse. J Neurosci (2005) 2.40
Metabotropic glutamate receptors trigger postsynaptic protein synthesis. Proc Natl Acad Sci U S A (1993) 2.37
Prolonged epileptiform discharges induced by altered group I metabotropic glutamate receptor-mediated synaptic responses in hippocampal slices of a fragile X mouse model. J Neurosci (2005) 2.34
Effect of simvastatin on cognitive functioning in children with neurofibromatosis type 1: a randomized controlled trial. JAMA (2008) 2.30
Dendritic spines elongate after stimulation of group 1 metabotropic glutamate receptors in cultured hippocampal neurons. Proc Natl Acad Sci U S A (2002) 2.23
Homer interactions are necessary for metabotropic glutamate receptor-induced long-term depression and translational activation. J Neurosci (2008) 2.22
Minocycline promotes dendritic spine maturation and improves behavioural performance in the fragile X mouse model. J Med Genet (2008) 2.20
Deficits in trace fear memory and long-term potentiation in a mouse model for fragile X syndrome. J Neurosci (2005) 2.19
The group I mGlu receptor agonist DHPG induces a novel form of LTD in the CA1 region of the hippocampus. Neuropharmacology (1998) 2.16
Key role for gene dosage and synaptic homeostasis in autism spectrum disorders. Trends Genet (2010) 2.14
Fragile X mental retardation protein deficiency leads to excessive mGluR5-dependent internalization of AMPA receptors. Proc Natl Acad Sci U S A (2007) 2.10
The fragile X mental retardation protein is associated with poly(A)+ mRNA in actively translating polyribosomes. Hum Mol Genet (1997) 2.08
Fenobam: a clinically validated nonbenzodiazepine anxiolytic is a potent, selective, and noncompetitive mGlu5 receptor antagonist with inverse agonist activity. J Pharmacol Exp Ther (2005) 2.08
The state of synapses in fragile X syndrome. Neuroscientist (2009) 2.07
Identification of small molecules rescuing fragile X syndrome phenotypes in Drosophila. Nat Chem Biol (2008) 2.04
Open-label treatment trial of lithium to target the underlying defect in fragile X syndrome. J Dev Behav Pediatr (2008) 1.91
Metabotropic glutamate receptors trigger homosynaptic protein synthesis to prolong long-term potentiation. J Neurosci (2000) 1.89
Excess phosphoinositide 3-kinase subunit synthesis and activity as a novel therapeutic target in fragile X syndrome. J Neurosci (2010) 1.89
Reduced cortical synaptic plasticity and GluR1 expression associated with fragile X mental retardation protein deficiency. Mol Cell Neurosci (2002) 1.87
Metabotropic glutamate receptor subtype 5 antagonists MPEP and MTEP. CNS Drug Rev (2006) 1.86
The emerging role of synaptic cell-adhesion pathways in the pathogenesis of autism spectrum disorders. Trends Neurosci (2009) 1.84
Excess protein synthesis in Drosophila fragile X mutants impairs long-term memory. Nat Neurosci (2008) 1.83
Requirement of protein synthesis for group I mGluR-mediated induction of epileptiform discharges. J Neurophysiol (1998) 1.80
Fragile X mental retardation protein induces synapse loss through acute postsynaptic translational regulation. J Neurosci (2007) 1.78
The fragile X mental retardation protein and group I metabotropic glutamate receptors regulate levels of mRNA granules in brain. Proc Natl Acad Sci U S A (2005) 1.74
The fragile X mental retardation protein is associated with ribosomes. Nat Genet (1996) 1.72
Delayed stabilization of dendritic spines in fragile X mice. J Neurosci (2010) 1.69
Cloning, expression, and gene structure of a G protein-coupled glutamate receptor from rat brain. Science (1991) 1.62
Protein translation in synaptic plasticity: mGluR-LTD, Fragile X. Curr Opin Neurobiol (2009) 1.61
FMRP is associated to the ribosomes via RNA. Hum Mol Genet (1996) 1.49
A reduced number of metabotropic glutamate subtype 5 receptors are associated with constitutive homer proteins in a mouse model of fragile X syndrome. J Neurosci (2005) 1.47
Physiological roles and therapeutic potential of metabotropic glutamate receptors. Ann N Y Acad Sci (2003) 1.41
Metabotropic glutamate receptor-mediated long-term depression: molecular mechanisms. Pharmacol Rev (2009) 1.40
Absence of metabotropic glutamate receptor-mediated plasticity in the neocortex of fragile X mice. Proc Natl Acad Sci U S A (2007) 1.37
From mTOR to cognition: molecular and cellular mechanisms of cognitive impairments in tuberous sclerosis. J Intellect Disabil Res (2009) 1.37
A PEDIGREE OF MENTAL DEFECT SHOWING SEX-LINKAGE. J Neurol Psychiatry (1943) 1.36
Early postnatal plasticity in neocortex of Fmr1 knockout mice. J Neurophysiol (2006) 1.36
Contribution of mGluR and Fmr1 functional pathways to neurite morphogenesis, craniofacial development and fragile X syndrome. Hum Mol Genet (2006) 1.36
Deregulation of EIF4E: a novel mechanism for autism. J Med Genet (2009) 1.31
Characterization and reversal of synaptic defects in the amygdala in a mouse model of fragile X syndrome. Proc Natl Acad Sci U S A (2010) 1.29
Elevated glycogen synthase kinase-3 activity in Fragile X mice: key metabolic regulator with evidence for treatment potential. Neuropharmacology (2008) 1.28
Coupling of inositol phospholipid metabolism with excitatory amino acid recognition sites in rat hippocampus. J Neurochem (1986) 1.26
Increased GABA(B) receptor-mediated signaling reduces the susceptibility of fragile X knockout mice to audiogenic seizures. Mol Pharmacol (2009) 1.20
Mechanistic relationships between Drosophila fragile X mental retardation protein and metabotropic glutamate receptor A signaling. Mol Cell Neurosci (2008) 1.15
Aberrant early-phase ERK inactivation impedes neuronal function in fragile X syndrome. Proc Natl Acad Sci U S A (2008) 1.09
Drosophila fragile X mental retardation protein and metabotropic glutamate receptor A convergently regulate the synaptic ratio of ionotropic glutamate receptor subclasses. J Neurosci (2007) 0.99
Brief report: acamprosate in fragile X syndrome. J Autism Dev Disord (2010) 0.99
Loss of the fragile X mental retardation protein decouples metabotropic glutamate receptor dependent priming of long-term potentiation from protein synthesis. J Neurophysiol (2010) 0.96
Adult reversal of cognitive phenotypes in neurodevelopmental disorders. J Neurodev Disord (2009) 0.93
Metabotropic glutamate receptor-mediated use-dependent down-regulation of synaptic excitability involves the fragile X mental retardation protein. J Neurophysiol (2008) 0.90
Characterization of glutamate receptors induced in Xenopus oocytes after injection of rat brain mRNA. Neurosci Res (1988) 0.89
The role of molecular biology in psychiatry. Psychosomatics (1988) 0.77
LTP and LTD: an embarrassment of riches. Neuron (2004) 15.48
Learning induces long-term potentiation in the hippocampus. Science (2006) 7.46
Correction of fragile X syndrome in mice. Neuron (2007) 6.51
Altered synaptic plasticity in a mouse model of fragile X mental retardation. Proc Natl Acad Sci U S A (2002) 6.45
Chronic pharmacological mGlu5 inhibition corrects fragile X in adult mice. Neuron (2012) 4.31
Mutations causing syndromic autism define an axis of synaptic pathophysiology. Nature (2011) 4.13
The autistic neuron: troubled translation? Cell (2008) 3.81
NMDA receptor-dependent ocular dominance plasticity in adult visual cortex. Neuron (2003) 3.79
Ubiquitination regulates PSD-95 degradation and AMPA receptor surface expression. Neuron (2003) 3.62
How monocular deprivation shifts ocular dominance in visual cortex of young mice. Neuron (2004) 3.43
Reward timing in the primary visual cortex. Science (2006) 3.36
Molecular mechanism for loss of visual cortical responsiveness following brief monocular deprivation. Nat Neurosci (2003) 2.81
Effects of STX209 (arbaclofen) on neurobehavioral function in children and adults with fragile X syndrome: a randomized, controlled, phase 2 trial. Sci Transl Med (2012) 2.51
A unified model of NMDA receptor-dependent bidirectional synaptic plasticity. Proc Natl Acad Sci U S A (2002) 2.45
Synaptic dysfunction in neurodevelopmental disorders associated with autism and intellectual disabilities. Cold Spring Harb Perspect Biol (2012) 2.42
Hypersensitivity to mGluR5 and ERK1/2 leads to excessive protein synthesis in the hippocampus of a mouse model of fragile X syndrome. J Neurosci (2010) 2.42
Smaller dendritic spines, weaker synaptic transmission, but enhanced spatial learning in mice lacking Shank1. J Neurosci (2008) 2.27
New views of Arc, a master regulator of synaptic plasticity. Nat Neurosci (2011) 2.18
The pathophysiology of fragile X (and what it teaches us about synapses). Annu Rev Neurosci (2012) 2.16
Instructive effect of visual experience in mouse visual cortex. Neuron (2006) 2.12
Activation of NR2B-containing NMDA receptors is not required for NMDA receptor-dependent long-term depression. Neuropharmacology (2006) 2.10
Role for metabotropic glutamate receptor 5 (mGluR5) in the pathogenesis of fragile X syndrome. J Physiol (2008) 2.08
Extracellular signal-regulated protein kinase activation is required for metabotropic glutamate receptor-dependent long-term depression in hippocampal area CA1. J Neurosci (2004) 2.06
Lovastatin corrects excess protein synthesis and prevents epileptogenesis in a mouse model of fragile X syndrome. Neuron (2013) 2.00
Deprivation-induced synaptic depression by distinct mechanisms in different layers of mouse visual cortex. Proc Natl Acad Sci U S A (2007) 1.92
Bidirectional synaptic mechanisms of ocular dominance plasticity in visual cortex. Philos Trans R Soc Lond B Biol Sci (2009) 1.83
Obligatory role of NR2A for metaplasticity in visual cortex. Neuron (2007) 1.72
Reversal of disease-related pathologies in the fragile X mouse model by selective activation of GABAB receptors with arbaclofen. Sci Transl Med (2012) 1.72
Mechanism-based approaches to treating fragile X. Pharmacol Ther (2010) 1.49
Loss of Arc renders the visual cortex impervious to the effects of sensory experience or deprivation. Nat Neurosci (2010) 1.48
A morphological correlate of synaptic scaling in visual cortex. J Neurosci (2004) 1.48
Visual experience induces long-term potentiation in the primary visual cortex. J Neurosci (2010) 1.43
Translating glutamate: from pathophysiology to treatment. Sci Transl Med (2011) 1.42
Evidence for altered NMDA receptor function as a basis for metaplasticity in visual cortex. J Neurosci (2003) 1.41
A cholinergic mechanism for reward timing within primary visual cortex. Neuron (2013) 1.29
Cognitive dysfunction and prefrontal synaptic abnormalities in a mouse model of fragile X syndrome. Proc Natl Acad Sci U S A (2011) 1.26
Essential role for a long-term depression mechanism in ocular dominance plasticity. Proc Natl Acad Sci U S A (2009) 1.26
The ratio of NR2A/B NMDA receptor subunits determines the qualities of ocular dominance plasticity in visual cortex. Proc Natl Acad Sci U S A (2009) 1.26
Cannabinoid receptor blockade reveals parallel plasticity mechanisms in different layers of mouse visual cortex. Neuron (2008) 1.25
Activity-dependent regulation of NR2B translation contributes to metaplasticity in mouse visual cortex. Neuropharmacology (2006) 1.20
Pharmacological reversal of synaptic plasticity deficits in the mouse model of fragile X syndrome by group II mGluR antagonist or lithium treatment. Brain Res (2010) 1.14
Fragile X mental retardation protein and synaptic plasticity. Mol Brain (2013) 1.12
Learning reward timing in cortex through reward dependent expression of synaptic plasticity. Proc Natl Acad Sci U S A (2009) 1.12
Relative contribution of feedforward excitatory connections to expression of ocular dominance plasticity in layer 4 of visual cortex. Neuron (2010) 1.10
The BCM theory of synapse modification at 30: interaction of theory with experiment. Nat Rev Neurosci (2012) 1.08
Bidirectional modifications of visual acuity induced by monocular deprivation in juvenile and adult rats. J Neurosci (2006) 1.07
Significance of N-methyl-D-aspartate (NMDA) receptor-mediated signaling in human keratinocytes. J Cell Physiol (2004) 1.07
Thalamic activity that drives visual cortical plasticity. Nat Neurosci (2009) 1.06
STX209 (arbaclofen) for autism spectrum disorders: an 8-week open-label study. J Autism Dev Disord (2014) 1.02
Rapid structural remodeling of thalamocortical synapses parallels experience-dependent functional plasticity in mouse primary visual cortex. J Neurosci (2010) 1.01
The effects of L-amphetamine sulfate on cognition in MS patients: results of a randomized controlled trial. J Neurol (2009) 0.99
Group I metabotropic glutamate receptors: a role in neurodevelopmental disorders? Mol Neurobiol (2007) 0.99
Fragile x syndrome and autism: from disease model to therapeutic targets. J Neurodev Disord (2009) 0.98
A biophysically-based neuromorphic model of spike rate- and timing-dependent plasticity. Proc Natl Acad Sci U S A (2011) 0.97
Loss of the fragile X mental retardation protein decouples metabotropic glutamate receptor dependent priming of long-term potentiation from protein synthesis. J Neurophysiol (2010) 0.96
Stimulus-selective response plasticity in the visual cortex: an assay for the assessment of pathophysiology and treatment of cognitive impairment associated with psychiatric disorders. Biol Psychiatry (2011) 0.95
Recovery from monocular deprivation using binocular deprivation. J Neurophysiol (2008) 0.95
How the mechanisms of long-term synaptic potentiation and depression serve experience-dependent plasticity in primary visual cortex. Philos Trans R Soc Lond B Biol Sci (2013) 0.94
Stimulus for rapid ocular dominance plasticity in visual cortex. J Neurophysiol (2006) 0.92
Bidirectional ocular dominance plasticity of inhibitory networks: recent advances and unresolved questions. Front Cell Neurosci (2010) 0.89
Is metabotropic glutamate receptor 5 upregulated in prefrontal cortex in fragile X syndrome? Mol Autism (2013) 0.86
Promoting neurological recovery of function via metaplasticity. Future Neurol (2010) 0.86
Activation of mGluR5 induces rapid and long-lasting protein kinase D phosphorylation in hippocampal neurons. J Mol Neurosci (2010) 0.85
Activity-dependent NR2B expression is mediated by MeCP2-dependent epigenetic regulation. Biochem Biophys Res Commun (2008) 0.85
Courting a cure for fragile X. Neuron (2005) 0.83
The levo enantiomer of amphetamine increases memory consolidation and gene expression in the hippocampus without producing locomotor stimulation. Neurobiol Learn Mem (2009) 0.82
Lifting the mood on treating fragile X. Biol Psychiatry (2012) 0.78
Synaptic plasticity in an altered state. Neuron (2002) 0.75
Erratum: Visual recognition memory, manifested as long-term habituation, requires synaptic plasticity in V1. Nat Neurosci (2015) 0.75